Pub Date : 2021-04-26DOI: 10.18203/2319-2003.IJBCP20211648
Ravi H. Kudthni, F. Ahmed, Sangala Srimanth Madanna, Samba Siva Raju Derangula, Pothuru Anil Kumar
Background: The drug promotional literature is one of many sources for seeking information about the drugs to the busy medical practitioner. The aim of current study was to assess drug promotional literatures as per world health organization, criteria and categorize them and to analyse the claims in presented in DPL. Methods: Current study is a descriptive study in which pharmaceutical promotional materials were collected from selected out-patient departments of a tertiary care hospital, Kurnool. Printed drug promotional literatures for modern drugs were collected and an assessment was made whether the advertisements adhered to WHO criteria for medicinal drug promotion. Results: A total of 271 drug promotional literatures were collected. Information about the single drug was given in 127 (46.9%). 144 (53.1%) DPLs contain fixed-dose combination. Majority of drug promoted in collected DPLs were miscellaneous group 83 (30.8%) followed by antimicrobials 55(20.3%) and blood and cardiovascular drugs 37(13.1), gastrointestinal drugs 23(8.5%), drugs acting on endocrine system 23(84.5%). Generic name was mentioned in 229(84.5%) while brand name was mentioned in 271(100%) of DPL. Conclusions: The study concluded that the drug information provided in the promotional brochures can be incomplete and unreliable. Hence a physician should not rely solely on the DPL provided by medical representatives. All brochures circulated among prescribers must undergo a strict process of assessment regarding information provided, especially related to efficacy and safety.
{"title":"Evaluation of drug promotional literatures in a tertiary care hospital setting in South India","authors":"Ravi H. Kudthni, F. Ahmed, Sangala Srimanth Madanna, Samba Siva Raju Derangula, Pothuru Anil Kumar","doi":"10.18203/2319-2003.IJBCP20211648","DOIUrl":"https://doi.org/10.18203/2319-2003.IJBCP20211648","url":null,"abstract":"Background: The drug promotional literature is one of many sources for seeking information about the drugs to the busy medical practitioner. The aim of current study was to assess drug promotional literatures as per world health organization, criteria and categorize them and to analyse the claims in presented in DPL. Methods: Current study is a descriptive study in which pharmaceutical promotional materials were collected from selected out-patient departments of a tertiary care hospital, Kurnool. Printed drug promotional literatures for modern drugs were collected and an assessment was made whether the advertisements adhered to WHO criteria for medicinal drug promotion. Results: A total of 271 drug promotional literatures were collected. Information about the single drug was given in 127 (46.9%). 144 (53.1%) DPLs contain fixed-dose combination. Majority of drug promoted in collected DPLs were miscellaneous group 83 (30.8%) followed by antimicrobials 55(20.3%) and blood and cardiovascular drugs 37(13.1), gastrointestinal drugs 23(8.5%), drugs acting on endocrine system 23(84.5%). Generic name was mentioned in 229(84.5%) while brand name was mentioned in 271(100%) of DPL. Conclusions: The study concluded that the drug information provided in the promotional brochures can be incomplete and unreliable. Hence a physician should not rely solely on the DPL provided by medical representatives. All brochures circulated among prescribers must undergo a strict process of assessment regarding information provided, especially related to efficacy and safety.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"16 1","pages":"527"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78860707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-26DOI: 10.18203/2319-2003.IJBCP20211657
S. Nitya, M. Shanthi, R. Meenakshi, S. Kiruthika
Ondansetron a selective 5-HT3 receptor antagonist has been widely used as a prophylactic antiemetic for chemotherapy induced and anaesthesia related nausea and vomiting. Anaphylaxis and anaphylactoid reaction rarely occur in less than 1% of the patients and may lead to potentially life-threatening events. This study is one such rare case report of hypersensitivity reaction to intravenous ondansetron in a perioperative setting. Familiarity about anaphylactoid reactions to intravenous ondansetron among the health practitioners would help them to bring about a rational approach to decrease its incidence.
{"title":"Intravenous ondansetron induced hypersensitivity reaction: a case report","authors":"S. Nitya, M. Shanthi, R. Meenakshi, S. Kiruthika","doi":"10.18203/2319-2003.IJBCP20211657","DOIUrl":"https://doi.org/10.18203/2319-2003.IJBCP20211657","url":null,"abstract":"Ondansetron a selective 5-HT3 receptor antagonist has been widely used as a prophylactic antiemetic for chemotherapy induced and anaesthesia related nausea and vomiting. Anaphylaxis and anaphylactoid reaction rarely occur in less than 1% of the patients and may lead to potentially life-threatening events. This study is one such rare case report of hypersensitivity reaction to intravenous ondansetron in a perioperative setting. Familiarity about anaphylactoid reactions to intravenous ondansetron among the health practitioners would help them to bring about a rational approach to decrease its incidence.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"124 1","pages":"578"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87981467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-26DOI: 10.18203/2319-2003.IJBCP20211653
D. Sinha, Bhuwaneshwari Sinha, Santosh Kumar, A. Chandra
Background: Fluoroquinolone eye drops is being prescribed by Opthalmologist in many ocular diseases as conjunctivitis, keratitis, bacterial corneal ulcers etc in more and more amount. There are many brands of fluoroquinolones drugs available in Indian market. Costly drugs can lead to economic burden on patients. Modifications in pharmaceutical policy are required, and prices of the drug should be controlled in effective way for all the drugs. Hence this study was done to assess the cost variation of fluoroquinolones opthalmic solutions available in Indian market. Methods: The maximum and minimum price of each brand of the drug in INR was noted by using CIMS January to April 2020 edition and Drug Today April to June 2020 volume 1. The cost ratio and the percentage cost variation for individual drug brands was calculated. The cost of each eye drop was calculated. At last the cost ratio and percentage cost variation of various brands was compared. Results: Percentage variation in cost for fluoroquinolones eye preparations marketed in India was found to be Eye drop Ciprofloxacin (0.3%) of 5 ml:210.39, Eye drop Ciprofloxacin (0.3%) of 10 ml:162, Eye drop Gatifloxacin (0.3%) of 5 ml:156, Eye drop Moxifloxacin (0.5%) of 5 ml:196.95, Eye drop Ofloxacin (0.3%) of 5 ml:245.16, Eye drop Ofloxacin (0.3%) of 10 ml:62.5, Eye drop Norfloxacin (0.3%) of 5 ml:120.68, Eye drop Sparfloxacin (0.3%):8.31, Eye drop Lomefloxacin (0.3%):16.17. Conclusions: There is a wide difference in the cost of different brands of fluoroquinolones eye preparations available in India. The clinicians prescribing these drugs should be aware of these variations in cost to reduce the cost of drug therapy.
{"title":"Study of price variation analysis of fluoroquinolones eye drops manufactured by various pharmaceutical companies in India","authors":"D. Sinha, Bhuwaneshwari Sinha, Santosh Kumar, A. Chandra","doi":"10.18203/2319-2003.IJBCP20211653","DOIUrl":"https://doi.org/10.18203/2319-2003.IJBCP20211653","url":null,"abstract":"Background: Fluoroquinolone eye drops is being prescribed by Opthalmologist in many ocular diseases as conjunctivitis, keratitis, bacterial corneal ulcers etc in more and more amount. There are many brands of fluoroquinolones drugs available in Indian market. Costly drugs can lead to economic burden on patients. Modifications in pharmaceutical policy are required, and prices of the drug should be controlled in effective way for all the drugs. Hence this study was done to assess the cost variation of fluoroquinolones opthalmic solutions available in Indian market. Methods: The maximum and minimum price of each brand of the drug in INR was noted by using CIMS January to April 2020 edition and Drug Today April to June 2020 volume 1. The cost ratio and the percentage cost variation for individual drug brands was calculated. The cost of each eye drop was calculated. At last the cost ratio and percentage cost variation of various brands was compared. Results: Percentage variation in cost for fluoroquinolones eye preparations marketed in India was found to be Eye drop Ciprofloxacin (0.3%) of 5 ml:210.39, Eye drop Ciprofloxacin (0.3%) of 10 ml:162, Eye drop Gatifloxacin (0.3%) of 5 ml:156, Eye drop Moxifloxacin (0.5%) of 5 ml:196.95, Eye drop Ofloxacin (0.3%) of 5 ml:245.16, Eye drop Ofloxacin (0.3%) of 10 ml:62.5, Eye drop Norfloxacin (0.3%) of 5 ml:120.68, Eye drop Sparfloxacin (0.3%):8.31, Eye drop Lomefloxacin (0.3%):16.17. Conclusions: There is a wide difference in the cost of different brands of fluoroquinolones eye preparations available in India. The clinicians prescribing these drugs should be aware of these variations in cost to reduce the cost of drug therapy.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"48 1","pages":"561"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88137058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-26DOI: 10.18203/2319-2003.IJBCP20211656
R. Meenakshi, S. Nitya, S. Kiruthika, M. Shanthi
Fixed drug eruptions (FDE) are cutaneous adverse drug reaction characterized by well demarcated erythematous plaques which on removal of the offending agent resolves with residual hyperpigmentation patches at the site. FDE to nitroimidazoles and fluoroquinolones have nevertheless been infrequently reported. Awareness about the adverse reaction to the fluoroquinolone-nitroimidazole combination drug and also the likelihood of recurrence with same or similar drugs and the possible cross reaction is eminent. Hereby we report one such case of FDE to ciprofloxacin/tinidazole combination.
{"title":"Fixed drug eruption associated with fixed combination of fluoroquinolone-nitroimidazole","authors":"R. Meenakshi, S. Nitya, S. Kiruthika, M. Shanthi","doi":"10.18203/2319-2003.IJBCP20211656","DOIUrl":"https://doi.org/10.18203/2319-2003.IJBCP20211656","url":null,"abstract":"Fixed drug eruptions (FDE) are cutaneous adverse drug reaction characterized by well demarcated erythematous plaques which on removal of the offending agent resolves with residual hyperpigmentation patches at the site. FDE to nitroimidazoles and fluoroquinolones have nevertheless been infrequently reported. Awareness about the adverse reaction to the fluoroquinolone-nitroimidazole combination drug and also the likelihood of recurrence with same or similar drugs and the possible cross reaction is eminent. Hereby we report one such case of FDE to ciprofloxacin/tinidazole combination.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"1 1","pages":"576"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88709356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-26DOI: 10.18203/2319-2003.IJBCP20211649
Moumita Hazra
Background: Delamanid, a nitro-dihydro-imidazooxazole, is a bactericidal cell wall methoxy-mycolic and ketomycolic acids biosynthesis inhibitor in actively replicating, dormant, and intracellular tuberculosis, and both drugsusceptible and drug-resistant strains of M. tuberculosis and M. kansasii, decreasing hydrophobicity and facilitating better bacterial drug penetration. Delamanid promotes intracellular generation of microbiocidal nitrogen oxidative intermediaries including nitric oxide, toxic even to dormant M. tuberculosis. Ofloxacin, the racemic mixture and levofloxacin, the S-or levorotatory isomer of ofloxacin, are bactericidal to M. tuberculosis, MAC, M. fortuitum, and other atypical mycobacteria, with inhibitory effect on DNA gyrase, DNA topoisomerase IV and IL-1α, IL-6, IL-8. Bedaquiline, a novel diarylquinoline, inhibits mycobacterial adenosine triphosphate synthase of M. tuberculosis, disrupting mycobacterial energy metabolism and replication. Bedaquiline’s initial bacteriostatic action is followed by a bactericidal effect after 5-7 days. The objective was to perform a rational pharmacotherapeutic study of the prevalent prescription patterns of delamanid, ofloxacin, levofloxacin, and bedaquiline, among the multi-drug resistant tuberculosis patients, in global multi-centre tertiary care hospitals. Methods: A multi-centre, retrospective, observational and analytical study of clinical prescriptions of 100 multi-drug resistant tuberculosis patients in hospitals, were performed. For 24-48 weeks, these patients had been prescribed antitubercular drugs, like delamanid 100 mg and ofloxacin 400 mg twice daily, levofloxacin 750 mg and bedaquiline 400 mg once daily followed by 200 mg thrice weekly, as part of MDR-TB treatment regimens. The no. of prescriptions for each drug were recorded, and the corresponding prescription rates were statistically derived in percentages. Results: Delamanid was most commonly prescribed (32 prescriptions, 32%), followed by ofloxacin (29 prescriptions, 29%), levofloxacin (24 prescriptions, 24%), and bedaquiline (15 prescriptions, 15%). The completeness of the prescription contents, the dose of drug, the duration of treatment, the instructions of medication, the frequency of drug intake, the name of the drug and the dosage form of the drug were observed in 100% of prescriptions. Conclusions: Prescription frequency of delamanid was followed by ofloxacin, levofloxacin and bedaquiline. Prescription content analyses showed 100% completeness.
{"title":"A rational pharmacotherapeutic study of the prevalent prescription patterns of delamanid, ofloxacin, levofloxacin, and bedaquiline among the multi-drug resistant tuberculosis patients in global multi-centre tertiary care hospitals","authors":"Moumita Hazra","doi":"10.18203/2319-2003.IJBCP20211649","DOIUrl":"https://doi.org/10.18203/2319-2003.IJBCP20211649","url":null,"abstract":"Background: Delamanid, a nitro-dihydro-imidazooxazole, is a bactericidal cell wall methoxy-mycolic and ketomycolic acids biosynthesis inhibitor in actively replicating, dormant, and intracellular tuberculosis, and both drugsusceptible and drug-resistant strains of M. tuberculosis and M. kansasii, decreasing hydrophobicity and facilitating better bacterial drug penetration. Delamanid promotes intracellular generation of microbiocidal nitrogen oxidative intermediaries including nitric oxide, toxic even to dormant M. tuberculosis. Ofloxacin, the racemic mixture and levofloxacin, the S-or levorotatory isomer of ofloxacin, are bactericidal to M. tuberculosis, MAC, M. fortuitum, and other atypical mycobacteria, with inhibitory effect on DNA gyrase, DNA topoisomerase IV and IL-1α, IL-6, IL-8. Bedaquiline, a novel diarylquinoline, inhibits mycobacterial adenosine triphosphate synthase of M. tuberculosis, disrupting mycobacterial energy metabolism and replication. Bedaquiline’s initial bacteriostatic action is followed by a bactericidal effect after 5-7 days. The objective was to perform a rational pharmacotherapeutic study of the prevalent prescription patterns of delamanid, ofloxacin, levofloxacin, and bedaquiline, among the multi-drug resistant tuberculosis patients, in global multi-centre tertiary care hospitals. Methods: A multi-centre, retrospective, observational and analytical study of clinical prescriptions of 100 multi-drug resistant tuberculosis patients in hospitals, were performed. For 24-48 weeks, these patients had been prescribed antitubercular drugs, like delamanid 100 mg and ofloxacin 400 mg twice daily, levofloxacin 750 mg and bedaquiline 400 mg once daily followed by 200 mg thrice weekly, as part of MDR-TB treatment regimens. The no. of prescriptions for each drug were recorded, and the corresponding prescription rates were statistically derived in percentages. Results: Delamanid was most commonly prescribed (32 prescriptions, 32%), followed by ofloxacin (29 prescriptions, 29%), levofloxacin (24 prescriptions, 24%), and bedaquiline (15 prescriptions, 15%). The completeness of the prescription contents, the dose of drug, the duration of treatment, the instructions of medication, the frequency of drug intake, the name of the drug and the dosage form of the drug were observed in 100% of prescriptions. Conclusions: Prescription frequency of delamanid was followed by ofloxacin, levofloxacin and bedaquiline. Prescription content analyses showed 100% completeness.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"102 1","pages":"532"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78082775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-26DOI: 10.18203/2319-2003.IJBCP20211655
Ankit R. Mistry, Sapna Gupta, S. Malhotra
Polymicrobial induced nephrotoxicity (PIN) occurs more commonly in critically ill patients. Exposure to drugs often results in toxicity in kidney which represents a major control system maintaining homeostasis of body and thus is especially susceptible to xenobiotics. We present here an adverse drug reaction which is additive nephrotoxicity with combined antimicrobial use in critically ill patient. Blood urea and serum creatinine levels were raised much above the baseline after a fortnight of therapy. The suspected drugs were withdrawn leading to a gradual improvement and normalization of blood urea and serum creatinine levels This suggested a causal relationship which was possibly due to the administration of nephrotoxic antimicrobials. The present case highlights that critically ill patients on prolonged Polymicrobial therapy should be closely monitored, and dose increments should be made cautiously.
{"title":"Polymicrobial therapy induced nephrotoxicity: more is not always better","authors":"Ankit R. Mistry, Sapna Gupta, S. Malhotra","doi":"10.18203/2319-2003.IJBCP20211655","DOIUrl":"https://doi.org/10.18203/2319-2003.IJBCP20211655","url":null,"abstract":"Polymicrobial induced nephrotoxicity (PIN) occurs more commonly in critically ill patients. Exposure to drugs often results in toxicity in kidney which represents a major control system maintaining homeostasis of body and thus is especially susceptible to xenobiotics. We present here an adverse drug reaction which is additive nephrotoxicity with combined antimicrobial use in critically ill patient. Blood urea and serum creatinine levels were raised much above the baseline after a fortnight of therapy. The suspected drugs were withdrawn leading to a gradual improvement and normalization of blood urea and serum creatinine levels This suggested a causal relationship which was possibly due to the administration of nephrotoxic antimicrobials. The present case highlights that critically ill patients on prolonged Polymicrobial therapy should be closely monitored, and dose increments should be made cautiously.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"40 1","pages":"572"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83023276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-26DOI: 10.18203/2319-2003.IJBCP20211654
V. P.
Licofelone in osteoarthritis: is this the awaited drug? a systematic review - Osteoarthritis is a progressive joint disease
利可菲龙治疗骨关节炎:这是期待已久的药物吗?系统综述-骨关节炎是一种进行性关节疾病
{"title":"Licofelone in osteoarthritis: is this the awaited drug? a systematic review","authors":"V. P.","doi":"10.18203/2319-2003.IJBCP20211654","DOIUrl":"https://doi.org/10.18203/2319-2003.IJBCP20211654","url":null,"abstract":"Licofelone in osteoarthritis: is this the awaited drug? a systematic review - Osteoarthritis is a progressive joint disease","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"35 1","pages":"564"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88880459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-26DOI: 10.18203/2319-2003.IJBCP20211662
S. Sharif, Rubian S Sharif
What is the truth about the conspiracy theory of the COVID-19 microchip vaccine? The outbreak of the COVID-19 witnessed a vicious race of pharmaceutical firms to develop a vaccine that ends this disaster. Claims were forwarded that some firms funded by well-known foundations are in the process of developing such a vaccine so people wide world can be tracked. Such claims may have been based on Mr. Bill Gate’s announcement in an interview that through vaccination "we will have some digital certificates" which would be used to show who had recovered, been tested and ultimately who received a vaccine but he made no mention of microchips. The conspiracy theory is spreading around the world and its supporters are on the increase among the public as well as many healthcare professionals. The spread of the virus has been attributed to the introduction of 5G technology and many religious leaders attributed the crisis to punishment from God to the spread of local wars and mass killing, torturing and killing of Muslims in China and Myanmar gay and lesbian movement and marriages.
{"title":"COVID-19 vaccines: the dilemma when thinking as a patient","authors":"S. Sharif, Rubian S Sharif","doi":"10.18203/2319-2003.IJBCP20211662","DOIUrl":"https://doi.org/10.18203/2319-2003.IJBCP20211662","url":null,"abstract":"What is the truth about the conspiracy theory of the COVID-19 microchip vaccine? The outbreak of the COVID-19 witnessed a vicious race of pharmaceutical firms to develop a vaccine that ends this disaster. Claims were forwarded that some firms funded by well-known foundations are in the process of developing such a vaccine so people wide world can be tracked. Such claims may have been based on Mr. Bill Gate’s announcement in an interview that through vaccination \"we will have some digital certificates\" which would be used to show who had recovered, been tested and ultimately who received a vaccine but he made no mention of microchips. The conspiracy theory is spreading around the world and its supporters are on the increase among the public as well as many healthcare professionals. The spread of the virus has been attributed to the introduction of 5G technology and many religious leaders attributed the crisis to punishment from God to the spread of local wars and mass killing, torturing and killing of Muslims in China and Myanmar gay and lesbian movement and marriages.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"42 1","pages":"609"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75456797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-26DOI: 10.18203/2319-2003.IJBCP20211639
H. A. Butt, W. Ali, Warda Hussain, Amaidah Mir, W. Butt, Manahil Zulfiqar
Background: To determine awareness of medical students that utilize smartphone and their familiarity of medical applications. Methods: The questionnaire-based descriptive study was conducted in December 2019 and comprised medical students of first year and second year of the CMH Kharian Medical College, Kharian, and Nawaz Sharif Medical College, Gujrat, Gujranwala Medical College, Gujranwala and Mohi-ud-Din Islamic Medical College, Mirpur. Questionnaires were distributed in the classrooms and were filled by the students anonymously. SPSS 20 was used for statistical analysis. Results: Among the 770 medical students in the study, 747 (97%) had smartphones and 23 (3%) were using simple cell phones. Overall, 362 (47%) of the smart phone users were using some medical apps. Besides, 223 (29%) were aware of the medical apps but were not using them. Also, 655 (85%) students were not using any type of medical text eBooks through their phone, and only 115 (15%) had relevant text eBooks in their phones. Conclusions: A very low awareness among medical college students exists regarding smartphones as a gadget for improving medical knowledge.
{"title":"Pre COVID-19 usage of smartphones and medical applications among medical students","authors":"H. A. Butt, W. Ali, Warda Hussain, Amaidah Mir, W. Butt, Manahil Zulfiqar","doi":"10.18203/2319-2003.IJBCP20211639","DOIUrl":"https://doi.org/10.18203/2319-2003.IJBCP20211639","url":null,"abstract":"Background: To determine awareness of medical students that utilize smartphone and their familiarity of medical applications. Methods: The questionnaire-based descriptive study was conducted in December 2019 and comprised medical students of first year and second year of the CMH Kharian Medical College, Kharian, and Nawaz Sharif Medical College, Gujrat, Gujranwala Medical College, Gujranwala and Mohi-ud-Din Islamic Medical College, Mirpur. Questionnaires were distributed in the classrooms and were filled by the students anonymously. SPSS 20 was used for statistical analysis. Results: Among the 770 medical students in the study, 747 (97%) had smartphones and 23 (3%) were using simple cell phones. Overall, 362 (47%) of the smart phone users were using some medical apps. Besides, 223 (29%) were aware of the medical apps but were not using them. Also, 655 (85%) students were not using any type of medical text eBooks through their phone, and only 115 (15%) had relevant text eBooks in their phones. Conclusions: A very low awareness among medical college students exists regarding smartphones as a gadget for improving medical knowledge.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"11 1","pages":"479"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76243221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-26DOI: 10.18203/2319-2003.IJBCP20211663
V. R. Vismaya, Naiema Shajihan, M. Ramesh, Ambika Devi
Urinary tract infection (UTI), of varying severity is one of the most commonly encountered ailments in nephrology outpatient department (OPD). The commonest pathogens causing community acquired UTI (CAUTI) are E. Coli, Proteus mirabilis, Pseudomonas aeruginosa and Klebsiella pneumonia. There is a rapidly rising trend of antibiotic resistance among these uropathogens, may be due to indiscriminate antibiotic usage and poor patient compliance. We conducted a retrospective analysis of all culture proven UTI cases that attended the nephrology OPD of S. K. hospital, Trivandrum from August 2017 to July 2019 (24 months). 130 males and 121 females were included in the study. The mean age of the study group was 62.8 years with a male predominance in the age group above 50 years and a female predisposition in less than 50 years group. Commonest pathogen isolated in urine culture was E. coli (52.98%) followed by Klebsiella (39.09%), Citrobacter (8.76%), Pseudomonas (8.37%), Enterobacter (2.39%), Enterococci (1.99%), Candida (1.59%), Acinetobacter (1.2%), Proteus (1.2%), Streptococci (1.2%) and Serratia (0.4%).
{"title":"Microbiological profile and antibiotic resistance pattern of urinary tract infection in a tertiary care hospital","authors":"V. R. Vismaya, Naiema Shajihan, M. Ramesh, Ambika Devi","doi":"10.18203/2319-2003.IJBCP20211663","DOIUrl":"https://doi.org/10.18203/2319-2003.IJBCP20211663","url":null,"abstract":"Urinary tract infection (UTI), of varying severity is one of the most commonly encountered ailments in nephrology outpatient department (OPD). The commonest pathogens causing community acquired UTI (CAUTI) are E. Coli, Proteus mirabilis, Pseudomonas aeruginosa and Klebsiella pneumonia. There is a rapidly rising trend of antibiotic resistance among these uropathogens, may be due to indiscriminate antibiotic usage and poor patient compliance. We conducted a retrospective analysis of all culture proven UTI cases that attended the nephrology OPD of S. K. hospital, Trivandrum from August 2017 to July 2019 (24 months). 130 males and 121 females were included in the study. The mean age of the study group was 62.8 years with a male predominance in the age group above 50 years and a female predisposition in less than 50 years group. Commonest pathogen isolated in urine culture was E. coli (52.98%) followed by Klebsiella (39.09%), Citrobacter (8.76%), Pseudomonas (8.37%), Enterobacter (2.39%), Enterococci (1.99%), Candida (1.59%), Acinetobacter (1.2%), Proteus (1.2%), Streptococci (1.2%) and Serratia (0.4%).","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"51 1","pages":"611"},"PeriodicalIF":0.0,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85224765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：